Manager TitleAgeSince
President 63 26/05/2010
Director TitleAgeSince
Director/Board Member 63 25/03/2010
Director/Board Member 85 31/05/2011
Director/Board Member 79 08/05/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.30%+7.41%+14.79%+92.69% 60.74B
+0.39%+0.30%+20.04%+98.33% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-0.56%-0.48%+85.57%+65.40% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average -0.45%+1.70%+44.35%+194.69% 46B
Weighted average by Cap. -0.48%+1.64%+44.30%+169.14%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-